Lena Degling Wikingsson

Lena Degling Wikingsson is the current CEO of Dilafor. Lena has also served as the CEO of Avaris AB and as a board member of Eurocine Vaccines AB.

Lena has over 10 years of experience in the biotech industry. Lena started their career as a board member of XNK Therapeutics, before becoming the CEO of Avaris AB in 2007. Lena held this position for three years before moving on to become the CEO of Simplexia in 2010.

In 2012, Lena returned to the world of vaccines when they joined the board of Eurocine Vaccines AB. Lena served on the board for four years before being appointed as the CEO in 2016. Lena held this position until 2018, when they took over as the CEO of Dilafor.

Lena Degling Wikingsson has a Ph. D. in Pharmaceutics from Uppsala University, with a focus on Vaccines, Drug delivery systems and Biologics. Lena also has a Master of Science (M.Sc.) in Pharmacy from Uppsala University. Lena has done board work in privately held companies through Grant Thornton seminars, and is currently the CEO of such a company.

Some individuals on their team include Ann-Sofie Sternås - Head of Intellectual Property, Kjell Gunnarsson - Head of Non-Clinical Safety & Toxicology, and Per Blom - Head of Safety.